In a rare Federal Circuit decision under the Defend Trade Secrets Act (DTSA), 18 U.S.C. §
The district court granted a temporary restraining order and preliminary injunction in favor of
In the early 2000s, Insulet began developing wearable insulin pump technology.
In 2011,
In 2023, reports surfaced that Medtronic had started a due diligence process to acquire
To establish a preliminary injunction, the court must find that "(1) the plaintiff has a likelihood of success on the merits of his claim; (2) the plaintiff does not have an adequate remedy at law such that it will suffer irreparable harm without the injunction; (3) this harm is greater than the injury the defendant will suffer if the injunction is granted; and (4) the injunction will not harm the public interest." Concrete Mach. Co. v.
In a scathing opinion by
- Failing to discuss
EOFlow's argument that the trade secret misappropriation claim was barred by the three-year statute of limitations under the DTSA.
- Failing to identify the alleged trade secrets with sufficient particularity.
- Failing to adequately analyze whether Insulet took reasonable steps to protect specific information alleged to be a trade secret.
- Failing to adequately assess whether the alleged trade secret information was generally known or reasonably ascertainable through other proper means, such as reverse engineering, or from the plaintiff's published patent disclosures.
- Failing to sufficiently evaluate whether the alleged trade secret information had independent economic value.
- Failing to properly analyze whether the plaintiff established irreparable injury.
- Failing to "meaningfully engage with the public interest prong."
The Federal Circuit opinion is significant because DTSA cases are relatively rare in any circuit, but especially the Federal Circuit. This opinion, written by the well-respected
It also serves as a reminder of the trade-off between trade secrets and patents. In exchange for obtaining the exclusive rights inherent in patent protection, inventors must disclose their invention to the public. Doing so necessarily curtails their ability to claim trade secret protection over their invention because public disclosure is the antithesis of secrecy. As one example of the district court's failure to adequately weigh facts concerning the secrecy of the alleged trade secret, the Federal Circuit focused on
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
Hopkins &
San Jose
CA 95113
Tel: 408286 9800
Fax: 408998 4790
E-mail: ccullen@hopkinscarley.com
URL: www.hopkinscarley.com/
© Mondaq Ltd, 2024 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source